{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:15:01Z","timestamp":1792192501626,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3882,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>Although the introduction of antipsychotic drugs in 1954 was a breakthrough in the treatment of patients with schizophrenia, these agents have a number of adverse effects that limit effectiveness and compliance. The atypical antipsychotic drugs provide an improved tolerability profile, particularly in minimizing extrapyramidal side effects; however, they are associated with significant weight gain, which may be related to growing evidence linking the atypical agents with diabetes and hyperlipidemia. Ziprasidone, a new atypical antipsychotic drug, was demonstrated in clinical trials to be more efficacious than placebo and similar in efficacy to haloperidol in the treatment of schizophrenia. Like the existing atypical agents, ziprasidone has a rate of extrapyramidal side effects similar to that of placebo and does not cause significant elevations in prolactin levels. In contrast, ziprasidone has a low propensity for causing weight gain. For patients requiring an antipsychotic drug, ziprasidone represents a new treatment option with a limited adverse effect profile.<\/jats:p>","DOI":"10.1592\/phco.21.7.717.34575","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T09:55:05Z","timestamp":1086947705000},"page":"717-730","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Ziprasidone, a New Atypical Antipsychotic Drug"],"prefix":"10.1002","volume":"21","author":[{"given":"Ryan M.","family":"Carnahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"87","volume-title":"The medical basis of psychiatry","author":"Tsuang M.T.","year":"1994"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00152-3"},{"issue":"12","key":"e_1_2_1_5_2","first-page":"28","article-title":"Assessing the effects of atypical antipsychotics on negative symptoms","volume":"59","author":"Collaborative Working Group on Clinical Trial Evaluations","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.4.466"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/00048679609076070"},{"key":"e_1_2_1_8_2","first-page":"11","article-title":"Compliance with antipsychotic drug treatment: influence of side\u2010effects","volume":"382","author":"Fleischhacker W.W.","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(96)00010-7"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm950625l"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05830.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.4.466"},{"issue":"11","key":"e_1_2_1_13_2","first-page":"4","article-title":"Preclinical pharmacology of neuroleptics: focus on new generation compounds","volume":"57","author":"Richelson E.","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP\u201088 059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger T.F.","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_15_2","unstructured":"SchmidtA.W. LebelL.A. JohnsonC.G. et al.The novel antipsychotic ziprasidone has a unique human receptor binding profile compared with other agents [abstr]. Presented at the 153rd annual meeting of the American Psychiatric Association Chicago IL May 2000."},{"key":"e_1_2_1_16_2","unstructured":"Food and Drug Administration Center for Drug Evaluation Research. Transcript of psychopharmacological drugs advisory committee meeting July 19 2000. Available fromhttp:www.fdq.govohrmsdocketsaccder00.htmPsychopharmacologic20Drugs. Accessed September 1 2000."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00147.x"},{"issue":"1","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1046\/j.1365-2125.2000.00151.x","article-title":"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions","volume":"49","author":"Prakash C.","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817"},{"issue":"1","key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1046\/j.1365-2125.2000.00149.x","article-title":"The pharmacokinetics of ziprasidone in patients with normal and impaired hepatic function","volume":"49","author":"Everson G.","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1046\/j.1365-2125.2000.00150.x","article-title":"The pharmaco\u2010kinetics of ziprasidone in subjects with normal and impaired renal function","volume":"49","author":"Aweeka F.","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00148.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00156.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00154.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00157.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00153.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00152.x"},{"issue":"1","key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1046\/j.1365-2125.2000.00155.x","article-title":"The effects of ziprasidone on steady\u2010state lithium levels and renal clearance of lithium","volume":"49","author":"Apseloff G.","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200003000-00010"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","unstructured":"KeckP.E.Jr IceK. MandelF. et al.A 3\u2013week double blind randomized trial of ziprasidone in the acute treatment of mania [abstr]. Presented at the 22nd congress of the Collegium Internationale Neuro\u2010Psychopharmacologicum Brussels Belgium July 2000.","DOI":"10.1016\/S0924-977X(00)80328-4"},{"key":"e_1_2_1_31_2","unstructured":"ReevesK.R. SwiftR.H. HarriganE.P.A randomized double\u2010blind comparison of rapid\u2010acting intramuscular ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation [abstr]. Presented at the 153rd annual meeting of the American Psychiatric Association Chicago IL May 2000."},{"key":"e_1_2_1_32_2","unstructured":"ReevesK.R. SwiftR.H. HarriganE.P.Rapid\u2010acting intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation: results of two double\u2010blind randomized fixed\u2010dose studies [abstr]. Presented at the 153rd annual meeting of the American Psychiatric Association Chicago IL May 2000."},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","unstructured":"DanielD.G. BrookS. ReevesK.An overview of the efficacy and safety of rapid\u2010acting intramuscular ziprasidone [abstr]. Presented at the 22nd congress of the Collegium Internationale Neuro\u2010Psychopharmacologicum Brussels Belgium July 2000.","DOI":"10.1016\/S0924-977X(00)80305-3"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4\u2013week placebo\u2010controlled trial","volume":"140","author":"Keck P.","year":"1998","journal-title":"Psychopharmacology"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"e_1_2_1_36_2","unstructured":"AratoM. O'ConnorR. BradburyJ.E. et al.Ziprasidone in the long\u2010term treatment of negative symptoms and prevention of exacerbation of schizophrenia [abstr]. Presented at the 153rd annual meeting of the American Psychiatric Association Chicago IL May 2000."},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","unstructured":"HirschS. PowerA. KisslingW.A 28\u2010week comparison of flexible\u2010dose ziprasidone with haloperidol in outpatients with stable schizophrenia [abstr]. Presented at the 153rd annual meeting of the American Psychiatric Association Chicago IL May 2000.","DOI":"10.1016\/S0924-977X(99)80273-9"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","unstructured":"SimpsonG. PotkinS. WeidenP. O'SullivanR.L. RomanoS.Benefits of ziprasidone in stable outpatients with schizophrenia switched from conventional antipsychotics olanzapine or risperidone [abstr]. Presented at the 22nd congress of the Collegium Internationale Neuro\u2010Psychopharmacologicum Brussels Belgium July 2000.","DOI":"10.1016\/S0924-977X(00)80304-1"},{"key":"e_1_2_1_39_2","volume-title":"Geodon (ziprasidone) package insert","author":"Pfizer Inc.","year":"2001"},{"key":"e_1_2_1_40_2","unstructured":"DanielD.G. WeidenP.J. O'SullivanR.L.Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics olanzapine or risperidone [abstr]. Presented at the 22nd congress of the Collegium Internationale Neuro\u2010Psychopharmacologicum Brussels Belgium July 2000."},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1998.8.151"},{"issue":"11","key":"e_1_2_1_42_2","first-page":"40","article-title":"Side effects of new antipsychotic agents","volume":"57","author":"Casey D.E.","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_43_2","volume-title":"Zyprexa (olanzapine) package insert","author":"Eli Lilly and Company","year":"1998"},{"key":"e_1_2_1_44_2","volume-title":"Seroquel (quetiapine) package insert","author":"Zeneca Pharmaceuticals","year":"1999"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00158-3"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(97)00036-4"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.7.717.34575","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.7.717.34575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:53:25Z","timestamp":1761065605000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.7.717.34575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1592\/phco.21.7.717.34575"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.7.717.34575","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}